特应性皮炎患者长期口服糖皮质激素与安全性结局
这项在韩国健康保险审查评价院数据库(2012年1月1日至2021年10月31日)中开展的巢式病例对照研究,纳入2013至2020年间1 025 270例成人特应性皮炎患者,将164 809例发生11种不良事件之一者与328 303例从未发生这些事件者按性别、年龄、队列进入日期、随访时长和特应性皮炎严重程度匹配。长期口服糖皮质激素定义为每年累计处方超过30天或超过90天。多因素条件logistic回归显示,每年使用超过30天者总体不良事件风险未升高(AOR 1.00;95%CI 0.97-1.04),超过90天者风险轻度升高(AOR 1.11;95%CI 1.01-1.23);每累计或连续一年长期使用均观察到不良事件经历的轻度增加。作者认为该发现需未来研究进一步阐明。
要点
- 成人特应性皮炎患者每年口服糖皮质激素累计超过90天与11种不良事件复合终点风险轻度升高相关(AOR 1.11;95%CI 1.01-1.23)。
- 每年累计超过30天者未见总体不良事件风险升高(AOR 1.00;95%CI 0.97-1.04)。
- 暴露定义:每年口服糖皮质激素累计处方供应超过30天或超过90天。
- 病例组5533例(3.4%)与对照组10561例(3.2%)暴露超过30天;病例组684例(0.4%)与对照组1153例(0.4%)暴露超过90天。
- 每累计或连续一年长期使用均观察到不良事件经历的轻度增加。
适用人群与场景
- 韩国成人特应性皮炎患者,数据来自健康保险审查评价院数据库,研究期间为2012年1月1日至2021年10月31日。
- 纳入2013至2020年间1 025 270例成人特应性皮炎患者,其中164 809例发生11种不良事件之一者为病例组,328 303例从未发生这些事件者为对照组。
诊断标准与关键阈值
- 长期口服糖皮质激素定义为每年累计处方供应超过30天或超过90天。
- 复合结局包括11种不良事件:骨质疏松、骨折、2型糖尿病、高脂血症、高血压、心肌梗死、卒中、心力衰竭、股骨头坏死、白内障或青光眼。
研究设计与关键结果
- 研究类型:巢式病例对照研究,数据来自韩国健康保险审查评价院数据库,纳入1 025 270例成人特应性皮炎患者,匹配164 809例病例与328 303例对照(按性别、年龄、队列进入日期、随访时长和特应性皮炎严重程度匹配)。
- 病例组平均年龄39.4岁(SD 14.8),女性56.9%;对照组平均年龄39.3岁(SD 14.7),女性56.9%。
- 口服糖皮质激素超过30天暴露:病例组5533例(3.4%)vs 对照组10561例(3.2%)。
- 口服糖皮质激素超过90天暴露:病例组684例(0.4%)vs 对照组1153例(0.4%)。
- 每年使用超过30天者总体不良事件风险未升高:AOR 1.00(95%CI 0.97-1.04)。
- 每年使用超过90天者不良事件风险轻度升高:AOR 1.11(95%CI 1.01-1.23)。
- 每累计或连续一年长期使用均观察到不良事件经历的轻度增加。
证据类型、等级与局限
- 证据类型:巢式病例对照研究。
- 局限性:作者指出该发现需未来研究以充分阐明所观察到的结果。
对床旁实践的改变
- 作者认为,每年口服糖皮质激素累计超过90天与成人特应性皮炎患者不良事件风险轻度升高相关,该发现需未来研究进一步阐明。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The use of oral corticosteroids for prolonged periods may be associated with adverse events (AEs). Nevertheless, the risk of AEs with oral corticosteroids, especially among patients with atopic dermatitis (AD), has not been comprehensively investigated and lacks evidence on duration of treatment.
OBJECTIVE: To assess the association between long-term exposure to oral corticosteroids and AEs among adult patients with AD.
DESIGN, SETTING, AND PARTICIPANTS: This nested case-control study used data from the Health Insurance Review and Assessment Service database of South Korea between January 1, 2012, and October 31, 2021, which included 1 year prior to the cohort entry date of January 1, 2013, for assessing exclusion criteria and baseline characteristics, and 1 year after the study end date of October 31, 2020, to ensure a minimum duration for assessing exposure. Among the population of adults with AD, patients diagnosed with any of 11 AEs were matched with patients who had never received a diagnosis of any of the 11 AEs.
EXPOSURE: Long-term use of oral corticosteroids was defined as cumulative supply of more than 30 days or more than 90 days of oral corticosteroid prescription per year.
MAIN OUTCOMES AND MEASURES: We used multivariable conditional logistic regression analyses to measure the risk of 11 individual outcomes (osteoporosis, fracture, type 2 diabetes, hyperlipidemia, hypertension, myocardial infarction, stroke, heart failure, avascular necrosis, cataract, or glaucoma) as the composite outcome, controlling for potential confounders. We further classified the composite outcome to individual outcomes to evaluate the AE-specific risk.
RESULTS: Among 1 025 270 patients with AD between 2013 and 2020, 164 809 cases (mean [SD] age, 39.4 [14.8]; 56.9% women) were matched with 328 303 controls (mean [SD] age, 39.3 [14.7]; 56.9% women) for sex, age, cohort entry date, follow-up duration, and severity of AD, where the balance of most baseline characteristics was achieved. A total of 5533 cases (3.4%) and 10 561 controls (3.2%) were exposed to oral corticosteroids for more than 30 days, while 684 cases (0.4%) and 1153 controls (0.4%) were exposed to oral corticosteroids for more than 90 days. Overall, there was no increased risk of AEs with use of oral corticosteroids for more than 30 days (adjusted odds ratio [AOR], 1.00; 95% CI, 0.97-1.04), whereas the risk was slightly higher with use of oral corticosteroids for more than 90 days (AOR, 1.11; 95% CI, 1.01-1.23). The small elevation in experiencing an AE was observed with each cumulative or consecutive year of ever long-term use.
CONCLUSIONS AND RELEVANCE: This case-control study found a slightly increased risk of AEs associated with use of oral corticosteroids for more than 90 days per year, which warrants future research to fully elucidate the observed findings.
参考来源
- Jang YH, Choi EY, Lee H, et al. Long-Term Use of Oral Corticosteroids and Safety Outcomes for Patients With Atopic Dermatitis. JAMA Netw Open. 2024. PMID: 39028668. doi:10.1001/jamanetworkopen.2024.23563
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。